EPZM - Earnings call transcript Q1 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello, and welcome to Epizyme's Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session after the prepared remarks. [Operator Instructions] Please be advised that this call is being recorded at Epizyme's request.

I would now like to turn the call over to Alicia Davis.

begin. may You

Alicia Davis

good release, and XXXX today, issued epizyme.com. we results, Thank recent morning. progress press at found outlining can quarter in a which you, be Earlier our financial first

me the Business Q&A Paolo session. for and Shefali Tombesi, is On Financial Dr. with Rob CEO; will Chief Officer; Officer; Matt Medical Chief the Officer Bazemore, Agarwal, Chief Strategy Ros, and us call join

to be and Epizyme's XX-Q, views subject publicly representing Today's our Actual current relied statements and XX-K section and subsequent the filings. SEC views represent statements as discussion will materially Forms are risks of as include These We to Risk most expectations, important those differ call to may related our this obligation any undertake certain various no forward-looking factors uncertainties. not upon recent of forward-looking results date. which Factors to described our update as other plans should due of including statements. these in and

let to turn Rob. Rob? the Now, call over me

Rob Bazemore

their is challenges and first live thank where the us important We our Epizyme, to the amidst joining communities today. of provide COVID-XX you care all with our objectives. for the dedication industry faced progress the all safety has and work. employees out to we of pandemic. our care, corporate to This health first who Alicia very given on teams the of At and foremost is patients, started and significant the that to XXXX quarter our you, strong particularly Thank

that medical on and frontline clinical truly also and focused been us Their created to sincerest diseases this need like other the would know of TAZVERIK, all working to uncertainties further to Despite of we the have is on still commercial those of options our the ability and behalf On I remain with to long-term and we are organization, that commitment inspiration. treatment cancer treatment many the centers by serious caregivers patients' value. entire maximizing strengthening the gratitude pandemic, keep an safe. professionals, our the create new lives in people and potential of impact extend

potential we we quarter, and clinical their allow ongoing to families designed on continue pipeline, lost team our and well-being We've collaborators. momentum while and our our our have situation that commercializing us our impact business advancing on and our maintain that plans we and to business and the could were of TAZVERIK not of Last evaluate ensuring basis programs our our and to minimizing continuity safety an and plans the the sight this assessing uncertainties activated accordingly. our mission and early many business adjust to will disruptions

small and activities except to minimize in a In home, early from March, the we number critical and to operating facilities moving. away entire a remote have company time who working the while of been for essential personnel, labs keeping model shifted on rotation office

year. Our to on utilizing core objectives methods connected stay team and the virtual the safe and many focused them for available is our well, to

FDA-approved in sarcoma ES still This approved the XX epithelioid early EZHX an the of indicated following sarcoma. so approval treatment TAZVERIK and patients January, for for pleased and metastatic company It's made important were or locally only inhibitor market. specifically our the accelerated year with our and These aged performance with only first and and commercial the we're with launch first on course of advanced TAZVERIK's the milestones. transformative older a epithelioid far. led approval is or biopharmaceutical of in into This transition Epizyme, TAZVERIK of integrated fully patients successful pediatric adult for a by number treatment

their steady prescriptions of Within traction practices. treatment March, saw February throughout TAZVERIK we filled into and approval, and incorporating being were week with a physicians

an also Support Patient our Program. inbound in to increase peers' We and through hotline saw EpizymeNOW our medical questions request

medical liaisons key up field treatment to in fully to efforts the here last centers the prior ES and our all leading August. immediately us educational COVID-XX And started launch, in allowed pandemic reach science the to unfolding Our following U.S. the

organization sales customers. so into modest some launch engagement their field homes, refill have is COVID-XX and Epizyme impact has continues do that their treatment and on centers. other been sites patients Our by broad innovative restricted complemented had to on and new reach appears using limited to non-personal serve oncology approaches prescriptions the work, Overall, plans. already to access based our shelter-at-home and methods community among personal far, our academic remote This the built to or other have be to given virtual policies

medicine oral distribution the is visits outpatient helping TAZVERIK physician treatment. to an directly specialty our patient's and utilizes receive home. the commercial a TAZVERIK network a hospital It's eliminate to infrastructure that to to Importantly, their delivers need additional to for or pharmacy

launch, months weeks, have And for patients TAZVERIK on TAZVERIK. plans. ensure access. several for since the among commitment we to targeted health been patients is all our to new already eligible see both during refills that over coverage and last We've the securing continued have successful And prescriptions

approval. its to addition executing indication in initial months six patient for label larger population into which approval quickly In approaching just TAZVERIK, ES potential would our the are a an we program, our second from within expand additional

follicular supplemental patients, with treatment of TAZVERIK review the FDA. have priority prior is lymphoma for therapies least NDA under relapsed/refractory Our the received two for systemic who at

us This of and commercial with the readiness make occurs. XX, will when FL upon quickly approval our TAZVERIK, underway ensure to agency well We're launch ahead working in closely allow physicians target it June with activity of aware our to expansion we're treating PDUFA date.

In among hired training academic is for adopted field-based extensive in used how and of our the would employees be to market Our FL preparation has and we oncologists FL commercial conducted complete. hundreds launch, and have community team been third-line of TAZVERIK understand research setting.

of relapsed/refractory come to to an remissions up an their choosing FL want who standard when for patients than are and have current there approach ideal. heard long-lasting continues treating is as that among the options patients. physicians, important to treatment We therapy, consistently provide response Duration consideration FL no less

the with currently for remain result. well-tolerated unmet opportunity the therapy an to many as and patients issue toxicities need speaks population withdraw and this This in from with and a However the feedback product a a efficacy. therapies patient available durable meaningful

supporting feedback and that differentiated physicians believe mutation both Importantly, tells EZHX TAZVERIK the use their in of also FL profile intended us in and demonstrated once EZHX safety available. activity the wild-type populations, the

which potential who these We this would oncology option satisfy the with a about advisory needs. some well all of meeting patients a academic community input, virtual recently and reinforced top for conducted of FL and a centers TAZVERIK in physicians, believe U.S., represent the collective board confident on positioned dozen Based we are FL points. as unmet in its relapsed/refractory be we their new to and treatment lymphoma

personally FL to media physicians academic approaches of web variety non-personal channels, promotion forums. virtually well either or launch plans key We've a in and oncology other and digital social through selling include our augmented to centers as as

to We but assess to prepared launch. our will commercialization we needed landscape be continue the efforts fully and to this adjust expect execute we'll as

is require enrolling in a only this in confirmatory of underway, combination both well and number studies castration-resistant portion into currently our as small of patients for patients safety of Our these already the TAZVERIK year. studies prostate FL trial trials, are which run-in Each cancer. ES as the

enrollment initiations can that we're additional We're with investigators working site for as possible to so open quickly we sites, monitoring. trial complete our engaging and study as virtual and

directly then important We move this for expect portions into the complete stage. these to continue year trials to the and run-in efficacy expansion safety

combinations additional finalized also of tazemetostat treatment FL, or We for are investigator-sponsored open a have to in which number already for and enrollment. evaluate lines are trials being

of are we ability additional strategically and these to important to addition, value both and multiple tazemetostat indications for And are new combinations. In preparing create for in shareholders. for patients studies our

the position. first from cash in in first $X.X a which $XXX securities. with million ES months sales and we in net quarter is million with financial for for equivalents two Finally, of line cash, consensus TAZVERIK strong recorded performance. the TAZVERIK approximately commercialization, are We ended in marketable in We

evenly revenues of but milestones. divided are our on collaboration reminder, based a As quarter-by-quarter, specific aren't achievement

Our XXXX. at current remains fund therefore well and financial to plans we least stand guidance into capitalized unchanged our operating

And XXXX an of In our our not TAZVERIK closing, goals and executing for with we the taken we've off advancing eyes ambitious our company. for plan research started efforts.

the Now, operate adapt to be more at than We and a that built same order ever, we business robust be we time, flexible and it's critical how as necessary. in resilient. plan our continuity business

a TAZVERIK, the a with differentiated next the have year treat continue follicular we We'll to including of opportunity progress for face-to-face. pursue. encouraging potential we the a to you have and now, our see pipeline the lymphoma. forward We on additional to in update range early programs look And to that number you cancers, product of continues, virtually to commercial-stage as in continue highly

the now Thank you all open line we'll for for joining us and Q&A.

Operator

Our first comes Instructions] with Citigroup. Mohit [Operator question Bansal from

line Your open. now is

Mohit Bansal

Great. or right little the the Could understand about it talk environment and a academic move right patients the convince is talk you Thanks to it given bit the how all dynamics taking now? you so easy of my early -- helping TAZVERIK, who at Is community? COVID adopter to is us difficult Basically, this centers help or and to point, you about little patient for bit if on can the progress. doctors quick now? congrats just And question -- question, launch far. us a could

Rob Bazemore

I'll Matt I Well, to start Ros comment said as specifically in question. my on remarks, I'll and ask Certainly. opening then your

ask you The of in, I to seeing are week sales, been think, how bit we've specific using able using to things. two of as with on more to approval, in great being come it impressed about raised I'll we all prescriptions our about launch have that and a first the very the question been and first -- drug ship following based speak so they just to first who's Matt booked far. it. ability the months the execute all, sales

Matt, So, it me let to kick you. over

Matt Ros

morning, place relates Good the have with We've to been centers for the prescriptions question. observed, launch, epithelioid sarcoma. our where majority the the to really Thanks as expectation, academic Sure. of to Mohit. regard it falling ES the being

a seen of multi-disciplinary States centers are academic often center. around this As the these have approximately disease, of United patients go with are reminder, patients. they XX There uniquely a diagnosed center population this that treatment when to or

proportionally we thus as occur. those utilization have far centers has the And would to been expected so, that in

Mohit Bansal

follow-up. then And a -- I helpful. if take have can Very a

market is how So it moving to dynamics FL ES. If I'm from market. are those correct, more driven community different now,

large can to you. to you approach Thank the Or make do preparation? it? what COVID that So how impact doesn't do sure differently you there plan

Matt Ros

Sure.

go patients the majority lymphoma, to the absolutely up of the centers. to actually majority observed spoken are patients In through past, those academic plan community ES the patients you're as of as these the ES follicular insights has our So the where the the XX% from right. of compared to in setting, overwhelming always to FL. in we've quickly for With leverage regard FL, launch then grouping expand infrastructure to and to planning based been

context promotional lymphoma the with either would approach sales has our other thoughtfully with with of regard regard of introducing And COVID, light in virtual promotional engagements. in engagements or how considered engagement our we those been to organization, starting programs other to follicular now speaker now things direct direct in engage matters think we're And to about with pivoting to that more regard.

and leveraged prescribers virtual type the methods until is but physician but in reopen. be the just that health we'll inconsistent our relationships thinking, differently, to organization with speak of we've their they engage the to on original parts start community terribly have hired, ability based that the the reach we'll not of talented bit practice, a in that engagement physician to community in our the So will which country through the care community

Mohit Bansal

very you Thank Excellent. much.

Operator

question Jefferies. Yee from next comes Michael Our with

is line open. Your now

Michael Yee

community follow-up update. morning you a the My dozen COVID? your approval of get relation a community it the about to thinking think and And approved once what pending to in did about you. question of how of feedback? you the meeting follicular. Thank is Good from Appreciate the guys. the of virtual is do kind trajectory setting And the gets KOLs despite question uptake in feedback

I The like get you after because million, reason the look which consensus I has the to some modeled other think think follicular, I Zydelig of ask and some at like of $XX $XX sales is they million. in comps

is think do that a in appreciate given how maybe whether the comp, that COVID talk you So comp? environment, utilization I to that reasonable about and a it.

Rob Bazemore

to you would your Matt, like and I'll then start add response? Certainly. to

Matt Ros

Sure. Absolutely.

of profile the With of So, significant and the many good with groups. the engagements community-based and the physicians that last academic-based level continue to interviews morning, to and Mike. months TAZVERIK, the of sought regard with to particularly regard both six perspective we've we've receive we feedback uptake had where over

very these available mentioned something The Rob of looking limited a particularly No feedback the provide prescribers as and benefits care consistent. currently durable choices and are for safe standard something that's is on call, of new, has benefit. And meaningful remission. the

regard COVID TAZVERIK quite that, oral we that to situation is that certainly well well. the as So to as with regard positioned in TAZVERIK an dynamic given fits that medicine nicely where believe very with we believe

regard in was actually indication indications, approved to mind a your for as question it as well. with With approved to keep Zydelig was that Zydelig regard the when two comp, CLL

their will provide the on meaningful out of arrive market. their So are TAZVERIK difficult attributes to to forward with physicians expectations to parse and into it's the this believe We based feedback performance. will that regard what looking around be molecule FL

Michael Yee

a or patients aware of sense Can on to the is there's I it? identified get sort drug they of you talking ask the anticipation since and is that already or pent-up some demand follow-up should out be based there them which

Matt Ros

ODAC with MSLs in increasing there's team awareness in to us. unanimous over quite facilitated time certainly regard we've field in then back the Shefali our ES predominant continues interest certainly has certainly Well, frankly her I FL ES, with performance seen our the level starting August, use. to -- And with think performance and of with been with in prescription despite that the for the regard that

be strong to very position to in a out come like a we So in uptake way. have we're going meaningful feel

Michael Yee

Thanks. Okay.

Rob Bazemore

add add a Matt's just to -- couple Yes. of couple I'll of Mike a things I'll things response.

also they're I think probably important.

question go. where has most patients also where expected use the centers, been limited. Our about we largely access anticipation probably the is the it's where that would from, ES been the that's and come asked Mohit and had It's academic has those

compared have centers. open to academic into We access community expect that to we'll more and probably States practices open begin earlier as the

is And think plays so we'll many of have the expectation office, see this will where us it's out, that earlier than ES allow it the likely patients of probably will some how academic -- I centers my are into the to access community but treated.

with the of been is payers. our the other gain in playing we've I our think one things ES since the doing favor work that launch to access

don't health those players. than targeted so most other been through update we're the And have that that's approved. the go FL to secured indication on of the process for now plans of is And we once

to We of particular And then launch. the we final in of thing oncology some their I the the the you patients prescriptions been that would seems and orals others say, impacting which see study all It or as less well. the data, have that treatment with oncology how their impact sure do targeted come in to prescriptions impacted than closely regards prescription this I'm for particularly require on infusion. for

in to just significantly. at impacted And been for but patients oncology TAZVERIK targeted seem these those that, not board just so nearly seen have the across so general and looking therapies not we've oral

this So, this home don't think out went we is delivered – we very we approval actual again, and post Matt I attributes through, attributes in we've be along the other the that favorable as of all product will taken we of by that TAZVERIK roll the through about research FDA. because it oral think can we that, an with – went at market as found TAZVERIK and the be talked

Michael Yee

Rob. Thanks, update. it. the Appreciate Appreciate

Operator

Our from Lebowitz Stanley. comes next Morgan David question with

now is open. Your line

David Lebowitz

monitoring see guess be? impact look going do R-squared taking when for might you might trials for forward for upcoming might how you question. you for and the you I environment my those studies? given when current Thank R-CHOP, and and recruiting see And presented of those internal at the very much how When be trials data analyses

Rob Bazemore

Certainly, David.

those efforts So doing. studies, and that virtually. on over we've specific we've things the side level, talk high turn all sites, things comment our about it moved I'll ability been commercial a efforts let of Shefali enroll and maybe monitor me the that the Matt at to our to clinical then all of some new about, do of Like talked to essentially to

stopped. has that in So, just way. happening work not It's a different

that, run-in remember small, that complete this to about, been the have safety fairly guided is you studies the asked number confirmatory informed safety the need enroll year that portion for we of we actually year because what that study. run-ins the dosing For the efficacy actually patients larger this their is previously make of and the would the transition. we And

able to need objective expansion. run-ins efficacy numbers be to that we the that year and So make that hit to the patients that we the complete expect on for still to do the based safety able to be we'll of have transition the

Maybe, ensure site some work that and I'll patients. has with talk have her Shefali just ongoing well we monitoring more of as both about the we're engage start doing of how the bit team specific around sites as a to done can

Shefali Agarwal

you. Thank Yeah.

this is morning. Shefali. So, Good

studies said, the this studies, require are two of Rob and as So they these confirmatory studies most small numbers year. very safety

We conducting also just of patients way on these have the and ensure studies running that monitor who virtual can to ongoing and a be are enrolled shifted trial. patients, to the

also get per traveling where at smooth the local basically procedures are places, to labs using labs methods feasible, monitoring, can leveraging to main it's scans protocol. allowing conduct to is and radiological whether that remote traveling nurses and use the access centers, safety virtual patients goal to Our the or they so and drug where the instead procedures doing different to of do they of

what engaging and with Additionally, what as that and our trial as opening can sites study we doing site initiations are is so additional possible for investigators also virtual monitoring quickly enrollment we complete

safety these FL studies timing, we mentioned, prostate. present at presentation the Rob safety expect time. but and on to And commit year the along to hopefully, this this for maybe because data ES mainly both are once – as with complete the based studies, And the not

David Lebowitz

you much. very Thank

Operator

Our question Cowen. next Werber comes with from Yaron

now Your open. line is

Yaron Werber

good morning. Hey,

So And I I ES first. have couple if about I a of apologize, experience maybe earlier. the ongoing missed it questions

that you just I kind XX is, maybe based patients we discount. month Is reasonable? about about first a thinking that's calculated gross-to-net little And on a we two assuming And then So of us gross-to-net not at sense looking can are But my question any of discount first follow-up. a sales. bit of XX% have XX%? a give

Rob Bazemore

Hi, Yaron, Rob. is this

think beginning that year at expect that hasn't probably would and between I the of to changed XX% what gross guided a So to and much the the first roughly XX% we year. over the is we be net

Yaron Werber

right. All Okay.

it So is coming And studies? patients? that's then the patient brought clinical from already you commercial actually experience new mostly reasonable. initial patients into Or

Rob Bazemore

patients in studies follow those had because therapy. with the off long-term of on of with come of patients their Most No. many had we the remember already them most clinical

we mostly market. the that open that patients from sourcing we're clinical -- these over. These are So converting from are are commercial the not from patients open trial

Yaron Werber

therapy we expect Okay. probably of sense and diagnosed so initial any slowdown? to new into then and lot can sense -- we are you identification. go accurately eligible you many would because And a who And a obviously pretty demand initial how any thinking this of there's then model a has have deep sort your for are changed do pent-up and all uptake currently patients

Rob Bazemore

to question? take want Yes. that to would you you --- like Matt do

Matt Ros

morning. Good Sure.

mentioned -- as new to refill seen first come So I has And have new scripts mean prescriptions continued diagnosed we've in now with well. Rob that those newly scripts in through certainly as the regard new into quarter. transitioned fact the patients

continuing regard performance community. So see TAZVERIK sarcoma quarter anticipate into epithelia type and would the in we And right beyond. we the second of the continue to with that to

Rob Bazemore

the I of I over indication a that large approved. in lot thing, occurs it's The about oftentimes launching first population important if a a you're that say would number you'll drug with drug is think keep early very mind, to Yaron other on large a when see stocking

don't this tease purchase. more pharmacies see our type have tumor, you really case the solid an of an we to demand. almost is actual so of being this But on-demand stocking It's And stocking out drug. from demand. In ultra-rare

Yaron Werber

lag what's available? And is -- And are diagnosis Okay. to or coming that I the of from sort would typically actually data? INI Is Thank already say therapy? that you. on the they -- requiring

Rob Bazemore

Sure.

there an of TAZVERIK, So for no for diagnosis the labeling use INIX is of requirement negativity.

utilization have have order who that. patients requirement there's As loss not epithelioid the But label, most XX% of know some tumors. INIX epithelioid But who in who for specific have sarcoma you patients use that diagnosed that the in negative TAZVERIK. And in we're are who we're sarcoma. most patients have the a in over -- INIX to seeing for part, seeing are sales other

Yaron Werber

maybe then just And terrific. question. a final Okay,

it who follicular of board do do going have have for from patients been the terms – prior therapies to third-line your how you a identified and and be? follicular of initial follicular In see fill ad sort while are therapy while? patients demand you to -- for a Is off been

And recently initial to a who's patient third-line out given to going into are going who of that to switch it just patients second-line patients to you. enroll be sort say from it's the Thank be failure let's Or this there? and going amount the relapsed/refractory of is drug?

Rob Bazemore

as our as will Good from Matt. Certainly. the to be bit research board used. you where well you the both experience, from a have talk as advisory I'll about market think we TAZVERIK question. let

Matt Ros

physicians as conducted level advisory and profile we are profile, the we've safety So molecule. executed the research of activity, well continue that's with the the same voluminous feedback duration TAZVERIK's provide that the as encouraged of to observed well from that's feedback market as associated its enthusiastic board that the about consistent activity that as recently particularly the been

the near with on the in progressed be who certainly we prior to that would TAZVERIK. where offer I see coming label for term With consistent have two or patients expect from, would more regard eligible patients we would that therapies

that patients in. to certainly we expect So come population of

new some regimens thought may come the process talked hypothesis and about we've will them in patients that to we around choose a as But challenges the of treatment a safety given that therapy of the back past, and encourage a opt in. existing in fact and out of had differentiated better profile, molecule believe we've with some certainly to

that patients challenging brand back and TAZVERIK's have into experience this treatments certainly like prior could one for in perhaps come those approval back a of had with treatment the So one. their market a with for come could

Yaron Werber

thank you. Great,

Operator

with comes question Leland from next Gershell Oppenheimer. Our

Your line now is open.

Leland Gershell

Hi. Good morning, board readout I on Thanks ad ask my guys. also comments. for taking to further market bit the that recently questions. a just and research you've your want

think Just you EZHX uptake about mutations just to as those could as activating that into may with what you we versus share think wild if trajectory type. Maybe color more be? some

if how Thanks. mutation? play mutation the going to And of that's COVID And have then physicians still even broad impact follow-up. -- could that may for you're any label be to agnostic there though the want for that I who label test given may a your

Rob Bazemore

Matt? Okay.

Matt Ros

Sure.

manage for channel is with to that I'll is fact certainly to suited plan we who situation established. be -- FL COVID specialty use the very thoughtful So considerations that believe well circumstances and with therapy built TAZVERIK, that community ease in regard care given to has facing this certainly distribution been mean, them COVID the physicians in for TAZVERIK And pharmacy to a is receiving so. fluid we've with believe with wish do start -- the very crisis patients the a to oral will again the we treatment the maybe as first. health the I an regard

itself The address option advisory we desire care the new that and candid. relapsed class been is the therapies standard it's be a benefit there's With acknowledgment regard new a advisers academic to or and feedback with living our there research research to and and our board, that remarkably consistent with. on feedback community for the disease do to from presents of provide patients these regard really patients our spoke for limited both consistently and current to that refractory a our with the no that

see disproportionate in type to With another in interest of regard level that to patients expect tests the wild-type as one mutation group use versus fundamentally yet mutation We a both would more patients well this patients, only we at well vis-à-vis utilization uptake -- and as having segments. we've mutation and both with point. either for profile wild see

Rob Bazemore

test the think among in is that, a done physicians is It Leland for us thing before to come that test important desire what -- that has the available. is we've this and EZHX. there's research not I institutions question and available have They our clinical medicine. without It's used strong today. that But testing can in think own the to we up that Many desire there We're way was strong about is see foundation seeing of test. through their just a I isn't diagnostic right. that even study.

therapy, I toxicities as the many drug. on can't two one the prior look rounds one. at is have I through issue that and of think the they of stay It about solves the they issue the of which need unmet profile been in need, talked some who've -- sustainable they remissions these or patients

they they're have therefore, looking so, for. what long-lasting don't And remissions. That's

in bit those or rates the patient it's a of in in of that the the XX% durability The different. the wild-type who keep those wild similar. the same. patient the reduction same looks durability a the response patients who is benefit who patients their has responds, mind type And a But our have EZHX are very in once an response were And with volume. our even didn't mutation did in whether about response patients tumor objective a is of studies have response patient

an of never objective just may the having response. threshold get it to benefiting, they're So

stay is data the drug remarks, patient benefit. tolerable in it think when which my long-lasting a that see in meets provides that on see about I is can opening talked durable totality, physicians unmet that they So it it safe and and I a need that

Leland Gershell

failure on ask, Thanks. be That's have would you wait words out of that but move does And that's of that formal they are go irrespective regimen take? say very who toxicities In favorable agent profile of the to of regimen efficacy on. efficacy the side TAZVERIK, and lot have alternative safety that then not for would a helpful. expect let's TAZVERIK easier may second-line simply another as maybe other given just the these a patients to to to switch options a

Bob Bazemore

off it's see Matt with but available. it speak on think treat to well who and -- and related proportion to adverse see There's want who a think referenced to we go of it's come patients currently the I toxicities have them. Yes, come that we in or they and just with back patients as research mainly off treatments events therapy the don't and the physicians did completely instructive I'll instructive I they are that ask Matt the to we research that therapy

would So, patient type second-line an in reason that a a candidate. the either seeing of patients And activity mutation, not therapy able to good thing we have -- whatever particularly who we the have believe they reasonable of if close be that given XX% a failed or tolerate to that. single-agent that's believe we're a EZHX on

there I we a address shows now. if anything research with anything who to need some don't again we is can And are people that our that of don't add know on TAZVERIK. And like those further. this come Matt right think to sadly you'd

Matt Ros

regard types us I that mean of coming agree. these has research challenges. of and No. therapy with That off certainly said. to about I challenges enlightened patients I well the because mean was tolerability of regard

a to given well well do do back point your and potential this them on for of safe TAZVERIK is the to and to in manageable come So, treatment manner. and the profile

Leland Gershell

of of drug may from maybe out drug And for Have get ahead you could if one I with for -- then follicular approved Thanks. -- you've any ES there and hold add. just to have level approval? patients data the the you the in quantify use interest the in gotten you of physicians FL refractory Great. more

Bob Bazemore

the described Yes, call the I beginning from we of lymphoma. with -- our was for a that prescriptions patient relapsed/refractory have in seen last follicular came actually we think one on that first

prescriptions to epithelioid continue in were that not sarcoma. indications We see some

have Some of those FL.

for for other who negative use the other Some who we've those has tumors have sarcoma. most part, been INIX that of patients But been have seen predominant patients epithelioid have the sarcomas.

Leland Gershell

All right, Thanks very terrific. much guys.

Operator

Lawson Barclays. Peter from comes question next Our Instructions] with [Operator

open. now is line Your

Peter Lawson

around use question any see if around agent? then color lines you negative in off-label it? agent been use follow-up tumors tazemetostat which kind Just seeing you'll you're other it's as seeing used Are of -- and what the potential combo get guess a use. you of around mono in any INI I details And

Bob Bazemore

Matt Well, sarcoma more to can seeing what in epithelia we're speak a bit I'll the ask if Yes. you Matt? use.

Matt Ros

appeared Good other ES have understanding. The has a and that to predominantly Peter. there then utilization question to regard with your morning TAZVERIK sarcomas with our Sure. with thus been use. And been majority have of monotherapy INIX around associated to INIX few regard malignancies far

Peter Lawson

majority changed that in are trend? April of sounds like it Has any that scripts And from use? in the way ES coming

Matt Ros

regard April Yes. changed with that through I much terribly regard of to finished with we've to really the seeing mean, month the the now what that performance we're utilization. prescription month, hasn't

are now the mentioned earlier, in drug predominant being patients Rob their both starting refills on As are patients we to on to but new to that patients the number these coming still February therapy. starting and of prescribed continue patients therapy, were certainly get see and ES

Peter Lawson

And from question a in just It quick that Great. to change OpEx going GAAP there Paolo. guidance for then non-GAAP. was seems a

Just Is milestone if a you could through that? change? that walk recognition

Robert Bazemore

So He hear was but him. -- don't off. Paolo, I it was I may question to dropped have think

reported go a results, if we So non-GAAP. the change question. answer There the we and GAAP actually to both I'll Peter, wasn't -- back QX you

the way to for pay because milestone most affect Pharmakon used by payment to this That highlighting it instrument cover the GAAP We we that the million are covered in. however was we that. in $XX We loan are Eisai a that thought people is interested milestone. the expenses the that the cash approval did cash case, one

cash. cash affect doesn't our it point view, of non-GAAP. doesn't affect It a the from So

that's we the that's not We'll well we coming the expense seen non-GAAP approval loan lymphoma. successful we're Pharmakon share be up, instrument. million be in the as follicular as $XX -- non-GAAP. covered by a loan have by We'll So by have another both our like that for will report with another and covered that case onetime milestone will that then. June GAAP the same. That go We if Pharmakon

Paolo Tombesi

is morning, Rob. think I know, is was there question. answered mute waited to Good if other don't happy you your just perfectly on any Hi. everyone. But intro for the This answer. follow-up I Paolo. I and

Peter Lawson

the clarification. for great. That's Thanks

Operator

back in remarks. questions for further no queue Mr. showing I'd am call Bazemore time. I closing this at to turn the like to

Rob Bazemore

And you great of a to a have for day. We Thanks and joining Okay. keeping as you Thank Take day-to-day. so who you look much. healthy care today. to all safe questions. the Have our everyone. hope we activity you thanks forward are your updated on progresses. all year And

Operator

conference participating. today's concludes this you for gentlemen, Thank call. and Ladies

disconnect. may You now

Epizyme (EPZM) 4 May 202020 Q1 Earnings call transcript